NCT07203287 Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease
| NCT ID | NCT07203287 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | The University of Texas Medical Branch, Galveston |
| Condition | Post Operative Pulmonary Complications |
| Study Type | INTERVENTIONAL |
| Enrollment | 490 participants |
| Start Date | 2025-08-26 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 490 participants in total. It began in 2025-08-26 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of the study is to determine which combination of neuromuscular blocking agent and reversal agent is safer to use during anesthesia for patients with chronic kidney disease. The main question it aims to answer is "The use of Cisatracurium with neostigmine leads to less post-operative pulmonary complications than Rocuronium with sugammadex."
Eligibility Criteria
Inclusion Criteria: * The subject is able and willing to provide and sign informed consent * The subject must be between 18 and 80 years of age * The subject should have chronic kidney disease as defined by glomerular filtration rate * The surgery must require general anesthesia with endotracheal intubation and neuromuscular blockade Exclusion Criteria: * Any patient under the age of 18 * Any patient over the age of 80 * Any patient with end stage renal disease * Any patient requiring dialysis * Patients presenting for Renal Transplantation * Pregnant Female * Any patient in the correctional system * Urgent or Emergent procedure * The surgery requires intubation post-operatively * Documented allergy to Rocuronium, Sugammadex, Cisatracurium or Neostigmine
Contact & Investigator
Michael Kinsky, MD
PRINCIPAL INVESTIGATOR
University of Texas
Frequently Asked Questions
Who can join the NCT07203287 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Post Operative Pulmonary Complications. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07203287 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07203287 currently recruiting?
Yes, NCT07203287 is actively recruiting participants. Contact the research team at mkinsky@utmb.edu for enrollment information.
Where is the NCT07203287 trial being conducted?
This trial is being conducted at Galveston, United States.
Who is sponsoring the NCT07203287 clinical trial?
NCT07203287 is sponsored by The University of Texas Medical Branch, Galveston. The principal investigator is Michael Kinsky, MD at University of Texas. The trial plans to enroll 490 participants.